LINDSEY MILLER: Open Payments
NPI 1770139024 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$480 in 34 payments from 14 companies in 2025. Trend: 2023 $98 · 2024 $183 · 2025 $480
Food & beverage: $480
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $156 |
| AstraZeneca Pharmaceuticals LP | 4 | $60 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Exact Sciences Corporation | 2 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $19 |
| Novo Nordisk Inc | 1 | $17 |
| Abbott Laboratories | 1 | $17 |
| Eisai Inc. | 1 | $17 |
Products named: LINZESS, AIRSUPRA, XIFAXAN, QULIPTA, EVKEEZA, Cologuard Collection Kit, UBRELVY, ZENPEP.
Industry payments across OK — which companies pay providers there.
